01:14 , Nov 16, 2018 |  BC Innovations  |  Emerging Company Profile

Virion: Harnessing viral defects

Virion Biotherapeutics Ltd. has capitalized on a naturally occurring viral mutation to develop broad-spectrum antivirals with lower potential for resistance than marketed products. Its lead compound, VH244, is in preclinical development to treat respiratory infections...
18:57 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

FDA approves Genentech flu therapy

FDA approved Xofluza baloxavir marboxil from Genentech Inc. to treat acute uncomplicated influenza in patients ages 12 and older who have been symptomatic for no more than 48 hours. The approval comes two months ahead...
17:57 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Coronavirus; influenza virus; HIV/AIDS; Ebola Cell culture and rat studies identified lipopeptide-based inhibitors of MERS-CoV S protein, Ebola virus glycoprotein and HIV env that could help treat Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola...
17:45 , Oct 24, 2018 |  BC Extra  |  Company News

FDA approves Genentech flu therapy

FDA approved Xofluza baloxavir marboxil from Genentech Inc. to treat acute uncomplicated influenza in patients ages 12 and older who have been symptomatic for no more than 48 hours. The approval comes two months ahead...
22:57 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

Genentech's flu therapy shortens time to symptom improvement by almost 30 hours in Phase III

Genentech Inc. reported additional data from the Phase III CAPSTONE-2 trial to treat influenza virus infection in patients at high risk of complications showing that baloxavir marboxil led to a median time to improvement of...
18:55 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Genentech's flu therapy meets in second Phase III

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said baloxavir marboxil met the primary endpoint of reducing time to improvement of symptoms vs. placebo in the double-blind Phase III CAPSTONE-2 trial to treat influenza virus...
18:16 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Genentech's flu therapy

Genentech Inc. said FDA accepted and granted Priority Review to its NDA for baloxavir marboxil (RG6152, S-033188) to treat acute uncomplicated influenza in patients ages 12 and older. Its PDUFA date is Dec. 24. The...
14:42 , Jun 26, 2018 |  BC Extra  |  Company News

Priority Review for Genentech's flu therapy

Genentech Inc. said FDA accepted and granted Priority Review to its NDA for baloxavir marboxil to treat acute uncomplicated influenza in patients ages 12 and older. Its PDUFA date is Dec. 24. The Roche (SIX:ROG;...
18:40 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Shionogic gets Japanese approval for flu vaccine

Shionogi & Co. Ltd. (Tokyo:4507) said Japan's Ministry of Health, Labour and Welfare (MHLW) approved an NDA for Xofluza baloxavir marboxil (S-033188), the company's single-dose oral therapy to treat influenza types A and B. The...
22:04 , Feb 23, 2018 |  BC Extra  |  Company News

Japan approves Shionogi's single-dose flu treatment

Shionogi & Co. Ltd. (Tokyo:4507) said Japan's Ministry of Health, Labour and Welfare (MHLW) approved an NDA for Xofluza baloxavir marboxil (S-033188), the company's single-dose oral therapy to treat influenza types A and B. The...